
INDEPENDENT AUDITORS REPORT

To the Members of MEDICAMEN LIFE SCIENCES PRIVATE LIMITED

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of Medicamen Life Sciences Private Limited (the Company), which comprise the Balance sheet as at March 31 2025, the Statement of Profit and Loss, including the statement of Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013, as amended (the Act) in the manner so required and give a true and fair view in conformity with Indian Accounting Standards (Ind AS) prescribed under section 133 of the Act and the other accounting principles Generally accepted in India, of the state of affairs of the Company as at March 31, 2025, its profit including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Key Audit Matters

Key Audit Matters are those matters that in our professional judgment were of most significance in our audit of the Financial Statements of the current period. These matters were addressed in the context of our audit of the Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. Reporting of key audit matters as per SA 701, Key Audit Matters are not applicable to the Company as it is an unlisted company.

Information other than the Financial Statements and Auditors' Report thereon

The Company's Board of Directors are responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexure(s) to Board's Report, but does not include the Financial Statements and our auditor's report thereon.

Our opinion on the Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Standalone Financial Statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Management's responsibility for the Financial Statements

The Company's Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these Financial Statements that give a true and fair view of the financial position, financial performance, changes in equity and Cash Flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable Assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and

The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report On Other Legal And Regulatory Requirements

As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the **Annexure "A"**, a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

As required by Section 143(3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;

this report are in agreement with the books of account;

(d) In our opinion, the aforesaid Financial Statements comply with the accounting standards specified under section 133 of the Act, read with rule 7 of the Companies (Accounts) Rules, 2014;

(e) On the basis of the written representations received from the directors as on March 31, 2025 taken on record by the board of directors, none of the directors is disqualified as on March 31, 2025 from being appointed as a director in terms of Section 164 (2) of the Act;

(f) Since the Company's turnover as per audited Financial Statements is less than Rs.50 Crores and its borrowings from banks and financial institutions at any time during the year is less than Rs.25 Crores, the Company is exempted from getting an audit opinion with respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such controls vide MCA notification No. G.S.R. 583 (E) dated June 13, 2017;

(g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, we report that section 197 is not applicable on private company. Hence reporting as per section 197(16) is not required

(h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us;

- I. The Company does not have any pending litigations which would impact its financial position.
- II. The Company did not have any long-term contracts including derivatives contracts for which there were any material foreseeable losses.
- III. There were no amounts which required to be transferred to the Investor Education and Protection Fund by the Company.
- IV. The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- V. The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- VI. Based on audit procedures which we considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.
- VII. The company has not declared or paid any dividend during the year in contravention of the provisions of section 123 of the Companies Act, 2013.

software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tempered with.

for Rai Qimat & Associates
Chartered Accountants
Firm Registration No.: 013152C



UDIN:25080857BMLCPK4259

Place: Gurugram
Date: 30.05.2025

Annexure "A" to the Independent Auditor's Report

(Referred to in paragraph 1 under 'Report On Other Legal And Regulatory Requirements' section of our report to the members of Medicamen Life Sciences Private Limited of even date)

On the basis of the information and explanation given to us during the course of our audit, we report that:

- (i) a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of all Property, Plant & Equipment.
- (B) The company is not having any intangible asset. Therefore, the provisions of Clause (i)(a)(B) of paragraph 3 of the order are not applicable to the company.
- b) Pursuant to the company's programme of verifying fixed assets in a phased manner, physical verification of fixed assets was conducted during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
- c) According to the information and explanations given to us title deeds of immovable properties, classified as fixed assets, are held in the name of the company.
- d) The company has not revalued its Property, Plant, and Equipment during the year. Therefore, the provisions of Clause (i)(d) of paragraph 3 of the order are not applicable to the company
- e) No proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder. Therefore, the provisions of Clause (i)(e) of paragraph 3 of the order are not applicable to the company.
- (ii) a) In our opinion, physical verification of inventory has been conducted at reasonable intervals by the management and the coverage and procedure of such verification by the management are appropriate. No material discrepancies were noticed on such verification.
- b) During any point of time of the year, the company has not been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets. Therefore, the provisions of Clause (ii)(b) of paragraph 3 of the order are not applicable to the company.
- (iii) In our opinion and based on the information and explanation given to us the company has not granted any loan, secured or unsecured to companies, firms, Limited Liability Partnerships, or other parties covered in the register maintained under section 189 of the Companies Act 2013. Accordingly, the provisions of clause 3 (iii) (a), (b) and(c) of the Order are not applicable to the Company.
- (iv) According to the information and explanations given to us and on the basis of representations of the management which we have relied upon, no loan, guarantee provided & no investment has been

applicable.

- (v) According to the information and explanations given to us, the Company has not accepted deposits from the public in terms of provisions of sections 73 to 76 of the Companies Act, 2013 therefore reporting under this clause is not applicable.
- (vi) According to the rules prescribed by the Central Government for the maintenance of cost records under section 148(1) of the Companies Act, 2013 is not applicable to the company therefore reporting under this clause is not required.
- (vii) a) According to the information and explanations given to us and the records of the Company examined by us, in our opinion, the Company has been regular in depositing statutory dues as applicable, with the appropriate authorities.

b) As of the year-end, according to the records of the Company and information and explanations given to us, there are no disputed statutory dues outstanding on the company.
- (viii) In our opinion and according to the information and explanations given to us, there is no any transaction not recorded in the books of account have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961)
- (ix) a) According to the records of the Company examined by us and the information and explanations given to us, the Company has not defaulted in repayment of any loan and interest thereon.

b) In our opinion and according to the information and explanations given to us, the company has not been a declared willful defaulter by any bank or financial institution or other lender.

c) In our opinion and according to the information and explanations given to us, the has not obtained any term loans, Accordingly, reporting under this clause is not applicable.

d) In our opinion and according to the information and explanations given to us, there are no funds raised on short-term basis which have been utilized for long-term purposes.

e) In our opinion and according to the information and explanations given to us, the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.

f) In our opinion and according to the information and explanations given to us, the company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies.
- (x) According to the information and explanations given to us, on an overall basis, the company has not raised any money by way of initial public offer or further public offer (including debt instruments) during the year.
- (xi) a) According to the information and explanations given to us and on the basis of representation of the management which we have relied upon, no fraud by the Company or on the company by its officers or employees has been noticed or reported during the year.

- b) During the year no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
 - c) As auditors, we did not receive any whistle-blower complaints during the year.
- (xii) Since the company is not a Nidhi company, therefore this clause is not applicable.
- (xiii) According to the information and explanations given to us, all transactions with the related parties are in compliance with section 177 and 188 of The Companies Act, 2013 as applicable and the details have been disclosed in the Financial Statements as required by the applicable accounting standards.
- (xiv) The company is not covered by section 138 of the Companies Act, 2013, related to appointment of internal auditor of the company. Therefore, the company is not required to appoint any internal auditor. Therefore, the provisions of Clause (xiv) of paragraph 3 of the order are not applicable to the Company.
- (xv) The company has not entered into any non-cash transaction with the directors or persons connected with him.
- (xvi)
- a. The company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934
 - b. The company has not conducted any Non-Banking Financial or Housing Finance activities during the year.
 - c. The company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India.
 - d. As per the information and explanations received, the group does not have any CIC as part of the group.
- (xvii) The company has not incurred cash loss in current financial year as well in immediately preceding financial year.
- (xviii) There has been no resignation of the previous statutory auditors during the year.
- (xix) On the basis of the financial ratios, aging and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, the auditor's knowledge of the Board of Directors and management plans, we are of the opinion that no material uncertainty exists as on the date of the audit report that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.
- (xx) There is no liability of the company under the provisions of section 135 of the Companies Act, relating to Corporate Social Responsibility. Therefore, the provisions of Clause (xx) of paragraph 3 of the order are not applicable to the Company.

(xxi) Reporting under this clause is not applicable to the company, since the company does not have any subsidiary company.

for Rai Qimat & Associates
Chartered Accountants
Firm Registration No. 013152C



UDIN:25080857BMLCPK4259

Place: Gurugram
Date: 30.05.2025

MEDICAMEN LIFE SCIENCES PVT. LTD.

CIN NO. U24290DL2022PTC403121, MSME NO. UDYAM-DL-08-0035438

Regd. Office: 1506, CHIRANJIV TOWER, 43, NEHRU PLACE, NEW DELHI-110019 (INDIA),
Corporate office: 1412 A, CHIRANJIV TOWER, 43, NEHRU PLACE, NEW DELHI-110019 (INDIA)

BALANCE SHEET AS AT 31 MARCH, 2025

(All amounts in Lacs of Rupees. Unless otherwise stated)

PARTICULARS	NOTE NO.	As at 31.03.2025	As at 31.03.2024
I. ASSETS			
1. Non-current assets			
(a) Property Plant & Equipment	3	79.16	74.57
(b) Capital work-in-progress	-	-	-
(c) Financial Assets			
(i) Investments	-	-	-
(ii) Trade Receivables	-	-	-
(iii) Loans	-	-	-
(d) Deferred Tax Assets (net)	-	-	-
(e) Other non-current assets	4	16.91	8.96
Total non-current assets		96.07	83.53
2. Current assets			
(a) Inventories	5	-	5.00
(b) Financial Assets			
(i) Investments	-	-	-
(ii) Trade Receivables	6	982.65	649.19
(iii) Cash and cash equivalents	7	16.98	15.07
(c) Current Tax Assets (Net)	-	-	-
(d) Other Current Assets	8	57.96	6.18
Total current-assets		1,057.60	675.44
TOTAL ASSETS		1,153.67	758.97
II. EQUITY AND LIABILITIES			
1. Equity			
(a) Equity Share Capital	9	1,000.00	913.50
(b) Other Equity	10	-700.59	-411.11
Total Equity		299.41	502.39
Liabilities			
2. Non-current liabilities			
(a) Financial Liabilities			
(i) Borrowings	11	278.36	30.48
(ii) Trade payables	-	-	-
(iii) Other financial liabilities (other than those specified in item (b))	-	-	-
(b) Provisions	-	-	-
(c) Deferred Tax Liabilities (net)	12	-0.30	0.60
(d) Other non-current liabilities	-	-	-
Total non-current liabilities		278.06	31.08
3. Current Liabilities			
(a) Short-term borrowings			
Financial Liabilities			
(i) Borrowings	13	306.40	92.60
(ii) Trade payables	14	144.01	82.70
(iii) Other financial liabilities (other than those specified in item (c))	-	-	-
(b) Other Current liabilities	15	125.79	50.20
(c) Provisions	-	-	-
(d) Current tax liabilities (Net)	-	-	-
Total current liabilities		576.20	225.50
TOTAL EQUITY & LIABILITIES		1,153.67	758.97

Summary of Significant Accounting Policies

1 & 2

As per our report of even date attached
for Rai Qimat & Associates
Chartered Accountants



Partner
M.No. 080857
(Firm Reg. No. 013152C)
UDIN: 25080857BMLCPK4259
Place : Gurgaon
Dated : 30.05.2025

for and on behalf of the Board of Directors
Medicamen Life Sciences Pvt. Ltd.

Kamal Kishore
Pahwa
Director
DIN : 09670162

Ashwani Kumar
Sharma
Director
DIN: 00325634

Rahul Bishnoi
Director
DIN: 00317960

MEDICAMEN LIFE SCIENCES PVT.LTD.

CIN NO. U24290DL2022PTC403121, MSME NO. UDYAM-DL-08-0035438

Regd. Office: 1506, CHIRANJIV TOWER, 43, NEHRU PLACE, NEW DELHI-110019 (INDIA),
Corporate office: 1412 A, CHIRANJIV TOWER, 43, NEHRU PLACE, NEW DELHI-110019 (INDIA)

Statement of Profit and Loss for the period 01.04.2024 to 31.03.2025

(All amounts in Lakh of Rupees. Unless otherwise stated)

Particulars	Note No.	For the year ended 31st March, 2025	For the year ended 31st March, 2024
I. REVENUE FROM OPERATIONS			
Sale of Goods/Services	16	1,108.38	692.00
II. Other income	17	0.80	1.01
III. Total revenue (1+2)		1,109.19	693.01
IV. Expenses			
(a) Purchase of Goods	18	181.64	126.57
(b) Stock Increase/Decreased	19	4.90	-4.90
(c) Employee benefits expense	20	1,030.27	794.74
(d) Finance Cost	21	11.06	2.01
(d) Depreciation and amortisation expense	3	11.31	8.48
(e) Other expenses	22	160.31	148.61
Total expenses		1,399.49	1,075.51
V. Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)		-290.30	-382.50
VI. Exceptional items		-	-
VII. Profit / (Loss) before tax (V - VI)		-290.30	-382.50
VIII. Tax expense:			
(a) Current Tax expenses relating to current year		-	-
(c) Deffered Tax	12	-0.30	-0.83
Total Tax Expenses		-0.30	-0.83
IX. Profit / (Loss) from continuing operations (9 ±10)		-290.00	-381.67
X. Earnings per equity share:- Basic & Diluted		-2.90	-4.18
XI. Weighted average number of equity Shares			

See accompanying notes forming part of the financial statements

As per our report of even date attached

for Rai Qimat & Associates

Chartered Accountants


CA Qimat Rai Garg
Partner

M.No.080857

(Firm Reg. No.013152C)


UDIN: 25080857BMLCPK4259

for and on behalf of the Board of Directors

Medicamen Life Sciences Pvt. Ltd.


Kamal Kishore
Pahwa
Director
DIN: 09670162


Ashwani Kumar
Sharma
Director
DIN: 00317960


Rahul Bishnoi
Director
DIN : 00317960

Place : Gurgaon

Dated : 30.05.2025

MEDICAMEN LIFE SCIENCES PVT. LTD.
CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2025

(All amounts in Lakh of Rupees. Unless otherwise stated)

PARTICULARS	2024-25	2023-24
A. Cash flow from Operating Activities		
Net Profit/(Loss) after tax from continuing operations	-290.00	-381.67
Non-cash adjustment to reconcile profit before tax to net cash flows		
Provision for Taxation	-	-
Adjustments for Deferred Tax	-0.30	-0.83
Financial Charges	11.06	2.01
Depreciation	11.31	8.48
Interest Income	0.80	-
Operating Profit before Working Capital Changes	-267.13	-372.01
Movements in working capital		
Increase/(decrease) trade payables	61.31	39.51
Increase/(decrease) in long term provisions	-	-
Increase/(decrease) in short term provisions	-	-
Increase/(decrease) in other current liabilities	75.58	33.06
Decrease/(Increase) in trade receivables	-333.53	-344.13
Decrease/(Increase) in inventories	5.00	-5.00
Decrease/(Increase) in long term loans and advances	-	-
Decrease/(Increase) in short term loans and advances	-	-
Decrease/(Increase) in other current assets	-51.78	-1.95
Decrease/(Increase) in other non current assets	-7.95	0.39
Direct taxes paid	-	-
Net Cash Flow from Operating Activities (A)	-518.50	-650.13
B. Cash Flow from Investing Activities		
Addition to Fixed Assets	-15.91	-53.77
Purchase of non-current investments	-	-
Interest Received	-0.80	-
Net Cash Flow from Investing Activities (B)	-16.71	-53.77
C. Cash Flow from Financing Activities		
Proceeds from issuance of share capital	86.50	564.50
Proceeds from Securities Premium	-	-
Net proceeds of long term borrowings	247.88	30.48
Net proceeds of short term borrowings	213.80	92.60
Net proceeds of Investment	-	-
Financial Charges	-11.06	-2.01
Net Cash Flow from Financing Activities (C)	537.12	685.57
NET INCREASE/(DECREASE) IN CASH & CASH EQUIVALENTS (A+B+C)	1.91	-18.33
Cash & Cash Equivalents at the beginning of the year	15.07	33.40
Cash & Cash Equivalents at the end of the year	16.98	15.07

As per our report of even date attached

for Rai Qimat & Associates

Chartered Accountants



CA Qimat Rai Garg

Partner

M.No.080857

(Firm Reg. No.013152C)

UDIN: 25080857BMLCPK4259

Place : Gurgaon

Dated : 30.05.2025

for and on behalf of the Board of Directors

Medicamen Life Sciences Pvt. Ltd.




Kamal Kishore
Pahwa
Director

DIN: 09670162



Ashwani Kumar
Sharma
Director

DIN: 00317960



Rahul Bishnoi
Director

DIN: 00325634

MEDICAMEN LIFE SCIENCES PVT. LTD.

Notes forming part of the financial statements

(All amounts in Lacs of Rupees. Unless otherwise stated)

Note 3 Fixed assets

Sr. No.	Tangible assets	Rate SLM	Gross block				Accumulated depreciation and impairment				Net block	
			Balance as at 1 April, 2024	Additions	Disposals	Balance as at 31 March, 2025	Balance as at 1 April, 2024	Depreciation for the year	Eliminated on disposal of assets	Balance as at 31 March, 2025	Balance as at 31 March, 2025	Balance as at 31 March, 2025
1	Computer	31.67%	4.81	3.82	-	8.63	1.98	1.28	-	3.26	5.37	
2	Furniture & Fixture	9.50%	20.75	-	-	20.75	2.48	1.74	-	4.22	16.53	
3	Office Equipment	19.00%	9.28	11.79	-	21.07	1.38	2.77	-	4.15	16.93	
4	Airconditioners	19.00%	1.97	0.29	-	2.26	0.46	0.29	-	0.75	1.51	
5	Books	9.50%	0.11	-	-	0.11	0.02	0.01	-	0.02	0.09	
6	Vehicle	11.88%	47.43	-	-	47.43	3.47	5.22	-	8.70	38.73	
	Total		84.35	15.91	-	100.26	9.79	11.31	-	21.10	79.16	

Sr. No.	Tangible assets	Rate SLM	Gross block				Accumulated depreciation and impairment				Net block	
			Balance as at 1 April, 2023	Additions	Disposals	Balance as at 31 March, 2024	Balance as at 1 April, 2023	Depreciation for the year	Eliminated on disposal of assets	Balance as at 31 March, 2024	Balance as at 31 March, 2024	Balance as at 31 March, 2024
1	Computer	31.67%	4.40	0.41	-	4.81	0.51	1.47	-	1.98	2.83	
2	Furniture & Fixture	9.50%	20.75	-	-	20.75	0.51	1.97	-	2.48	18.27	
3	Office Equipment	19.00%	3.61	5.67	-	9.28	0.16	1.21	-	1.38	7.90	
4	Airconditioners	19.00%	1.71	0.26	-	1.97	0.12	0.35	-	0.46	1.51	
5	Books	9.50%	0.11	-	-	0.11	0.00	0.01	-	0.02	0.09	
6	Vehicle	11.88%	-	47.43	-	47.43	-	3.47	-	3.47	43.96	
	Total		30.58	53.77	-	84.35	1.31	8.48	-	9.79	74.56	

for Rai Qimat & Associates
Chartered Accountants



CA Qimat Rai Garg
Partner
M.No.080857
(Firm Reg. No.013152C)
UDIN: 25080857BMLCPK4259
Place : Gurgaon
Dated : 30.05.2025

Kamal Kishore Pahwa

Kamal Kishore Pahwa
Director
DIN : 09670162

Ashwani Kumar Sharma

Ashwani Kumar Sharma
Director
DIN : 00325634

Rahul Bishnoi

Rahul Bishnoi
Director
DIN : 00317960

For and on behalf of the Board of Directors
MEDICAMEN LIFE SCIENCES PVT. LTD.

MEDICAMEN LIFE SCIENCES PVT. LTD.
Notes forming part of the financial statements as on 31.03.2025
(All amounts in Lacs of Rupees. Unless otherwise stated)

Particulars	As at 31st March 2025	As at 31st March 2024
Note 4 Other Non Current Assets (Misc. Exp.)		
Preliminary Expenses	19.15	11.20
Less W/off during the year	<u>2.24</u>	<u>2.24</u>
	<u>16.91</u>	<u>8.96</u>
Note 5 Inventories		
Inventories (at close)	-	4.90
Inventories (at commencement)	<u>-</u>	<u>-</u>
	<u>-</u>	<u>4.90</u>
Note 6 Trade Receivables		
Sundry Debtors	982.65	649.19
	<u>982.65</u>	<u>649.19</u>

Trade receivable Ageing as at 31st March'2024

Particulars	Less than 6 Months	6 Months -1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
(i) Undisputed Trade receivables – considered good	610.24	38.96	-	-	-	649.19
(ii) Undisputed Trade Receivables – considered doubtful	-	-	-	-	-	-
(iii) Disputed Trade Receivables considered good	-	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-
Total	<u>610.24</u>	<u>38.96</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>649.19</u>

Trade receivable Ageing as at 31st March'2023

Particulars	Less than 6 Months	6 Months -1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
(i) Undisputed Trade receivables – considered good	278.71	26.35	-	-	-	305.06
(ii) Undisputed Trade Receivables – considered doubtful	-	-	-	-	-	-
(iii) Disputed Trade Receivables considered good	-	-	-	-	-	-
(iv) Disputed Trade Receivables considered doubtful	-	-	-	-	-	-
Total	<u>278.71</u>	<u>26.35</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>305.06</u>

Note 7 Cash and Cash Equivalents

Cash in hand	0.10	0.08
Balances with banks	4.52	4.34
Fixed Deposits with bank	<u>12.36</u>	<u>10.65</u>
	<u>16.98</u>	<u>15.07</u>

Note 8 Other Current Assets

Tax Deducted at Sources	2.05	0.76
Tax Collect at Sources	0.46	0.46
Balance with Statutory Authorities (GST Recoverable)	0.05	0.51
Rent Security	1.72	1.72
Accrued Interest on FDR	0.31	0.29
Advance To Staff	52.60	1.30
Advance to suppliers	0.78	0.14
Gift Voucher	-	1.00
	<u>57.96</u>	<u>6.18</u>

Note 9 Capital Account

a) Equity Share Capital

Authorised (1,00,00,000 equity shares of Rs. 10/- each)	1,000.00	1,000.00
Issued, subscribed and paid up 40,10,000 equity shares of Rs. 10/- each fully paid)	1,000.00	913.50
Subscribed and fully paid up (Equity shares of Rs. 10/- each with voting rights)	1,000.00	913.50
	<u>1,000.00</u>	<u>913.50</u>

Particulars

As at
31st March 2025As at
31st March 2024

b) The reconciliation of the number of shares

Particulars

Particulars	As at 31st March 2025		As at 31st March 2024	
	Shares In Numbers	Amount	Shares In Numbers	Amount
Number of Shares at the beginning	2010000.00	201.00	2010000	201.00
Add: Shares issued during the year	7990000.00	712.50	7125000	712.50
Number of Shares at the End	10000000.00	913.50	9135000	913.50

c) The details of shareholders holding more than 5% shares

Name of Share Holder

1. Medicamen Biotech Limited (AAACM1217A)
2. Kamal Kishore Pahwa (AAOPP7107K)
3. Pramod Kumar Sharma (AAQPS9827F)

Name of Share Holder	As at 31st March 2025		As at 31st March 2024	
	Shares In Numbers	% Held	Shares In Numbers	% Held
1. Medicamen Biotech Limited (AAACM1217A)	6000000	60.00	5695100	62.34
2. Kamal Kishore Pahwa (AAOPP7107K)	4000000	40.00	1212450	13.27
3. Pramod Kumar Sharma (AAQPS9827F)	0	-	2227450	24.38
Total	10000000	100.00	9135000	100.00

d) Details of Number of shares held by Promoters

Shares held by promoters at the end of the 2024-25	Number of Shares			Percentage of shareholding		
	01.04.24 Opening	2024-25 Addition	31.03.2024 Closing	01.04.24 Opening	31.03.2025 Closing	2024-25 Change
Name of Promoters						
1. Medicamen Biotech Limited (AAACM1217A)	5695100	304900	6000000	63.75%	60.00%	-3.7%
2. Kamal Kishore Pahwa (AAOPP7107K)	1212450	2787550	4000000	11.88%	40.00%	28.12%
3. Pramod Kumar Sharma (AAQPS9827F)	2227450	-2227450	0	24.37%	0.00%	-24.37%
Total	9135000	865000	10000000	100.00%	100.00%	

Note 10 Other Equity

Opening balance		-411.11	-29.44
Add: Profit / Loss for the year		-289.48	-381.67
Closing balance		-700.59	-411.11
Share applicatin money received		-	-
Total		-700.59	-411.11

NOTE 11 LONG TERM BORROWINGS

AUSFB Term Loan 9001160646452834	300.00	
Car Loan from HDFC Bank	30.48	37.85
Less: Current Maturity	-52.12	-7.38
Total	278.36	30.48

NOTE 12 Deferred Tax

Deferred Tax Liability arising on account of:

Opening Deferred Tax Asset/Liability	0.60	1.43
WDV as per income tax act	75.69	71.37
WDV as per co. act	79.17	74.57
Difference	-3.47	-3.20
Current DTL	-0.90	-0.83
Closing Deferred Tax Asset/Liability	-0.30	0.60

Note 13 Borrowings

HDFC Bank Cash Credit	6.99	92.60
AU Small Finance Bank Ltd-CCL	299.42	
Total	306.40	92.60

Note 14 Trade Payables

Sundry Creditors	144.01	82.70
Total	144.01	82.70

Trade Payable ageing as at 31 March'2025

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 Month	6 Months - 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
(i) MSME	-	-	-	-	-	-
(ii) Others	56.33	26.37	-	-	-	82.70
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-
Total	56.33	26.37	-	-	-	82.70

Trade Payable ageing as at 31 March'2024

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Month	6 Months - 1 Year	1-2 Years	2-3 Years	More than 3 Years	
(i) MSME	-	-	-	-	-	-
(ii) Others	-	43.19	-	-	-	43.19
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-
Total	-	43.19	-	-	-	43.19

Particulars	As at 31st March 2025	As at 31st March 2024
Note 15 Other current liabilities		
Expenses Payable	-	10.27
TDS & GST Payable	22.49	15.80
PF & ESIC Payable	5.96	5.50
Audit Fees Payable	0.35	0.35
Salary Payable	4.35	1.64
Bonus Payable	16.52	2.45
Gratuity payable	1.52	-
Earned Leave Payable	22.47	-
Current Maturity of Long term Debts	52.12	7.37
Cheque issued but not presented	-	6.82
	125.79	50.20
Note 16 Revenue from operations		
Sale of Goods	1,108.38	692.00
	1,108.38	692.00
Note 17 Other Income		
Interest on FDR	0.80	1.01
	0.80	1.01
Note 18 Purchase of Goods		
Purchase of Traded Goods	181.64	126.57
	181.64	126.57
Note 19 Stock Increase/Decreased		
Opening Stock	4.90	-
Purchase during the year	181.64	126.57
Less: Consumption during the year	181.64	121.67
Closing stock	-	4.90
Stock Increase/Decreased	4.90	4.90
Note 20 Employee benefits expense		
Salary Exp.	638.46	505.84
Directors Remuneration	100.02	100.02
Contribution to ESIC	0.15	0.12
Contribution to PF	33.93	27.13
EPF Admin Charges	2.34	1.79
Leave Encashment	21.49	0.26
Bonus Expenses	22.55	0.29
Staff Welfare	18.20	11.46
Local Conveyance	0.20	12.13
Boarding & Loading Allowance	21.27	18.82
Conveyance Allowance	151.68	93.30
Incentive	17.06	9.24
Staff Training	1.41	14.34
Gratuity Payable	1.52	-
	1,030.27	794.74
Note 21 Financial Expenses		
Interest on TDS & GST	0.02	-
Interest on CCL	8.11	0.02
Interest on Car Loan	2.94	1.99
	11.06	2.01

	As at 31st March 2025	As at 31st March 2024
Note 22 Other Expenses		
Expenses (Direct)		
Carriage & Freight	0.74	0.48
Product Development	-	0.72
Product Registration	0.61	1.39
	<u>1.35</u>	<u>2.59</u>
Expenses (Indirect)		
Bank Charges	1.11	0.48
GST Expenses	-	0.05
Office Expenses	1.08	0.77
Water & Electricity	1.42	1.78
Telephone Expenses	4.24	3.26
Postage & Courier Expenses	5.46	4.57
Audit Fees	0.35	0.35
Business Promotion	87.98	75.46
Printing & Stationery	2.46	1.43
Repair & Main.	1.54	0.98
Vehicle Running & Maint	3.02	3.22
Tour & Travel	11.63	26.37
Insurance Exp.	1.97	8.93
Festival Celebration	2.36	3.86
Professional Expenses	0.86	0.51
Rent	8.46	6.87
Rent on Machinery	0.32	0.27
Software & Subscription	4.44	4.36
Board & Secretarial Expenses	0.16	0.30
Filing Fees	0.03	0.05
Preliminary Expenses w/off	2.24	2.24
Donation & charity	0.45	-
Depository Expenses	0.13	-
Professional Expenses (Advisory)	17.25	-
	<u>158.96</u>	<u>146.10</u>
	<u>160.31</u>	<u>148.69</u>

for Rai Qimat & Associates
Chartered Accountants



CA Qimat Rai Garg

Partner

M.No.080857

(Firm Reg. No.013152C)

UDIN: 25080857BMLCPK4259

Place : Gurgaon

Dated : 30.05.2025

For and on behalf of the Board of Directors
MEDICAMEN LIFE SCIENCES PVT. LTD.

Kamal Kishore
Pahwa
Director

DIN : 09670162

Ashwani Kumar
Sharma
Director

DIN : 00325634

R. Bishnoi

Director

DIN : 00317960